Abstract
X-Linked adrenoleukodystrophy (X-ALD) is a progressive metabolic condition affecting the adrenal glands and nervous system of males. Although variable in the age of onset and presentation in families, X-ALD does present in characteristic phenotypes including a devastating childhood form that affects 35% of boys with this genetic condition. The majority of males with X-ALD will also develop adrenal insufficiency, which may result in crisis. Early detection is desirable in order to prevent morbidity from this condition. We have recently developed a tandem mass spectroscopy method that allows this to be done during newborn screening for other genetic disorder. In this review, we discuss the rationale for early detection, its effect on treatment, and some of the uncertainties.
Similar content being viewed by others
References
Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999; 45(1): 100–10
Moser HW, Smith KD, Watkins PA, et al. X-linked adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw Hill, 2000: 3257–301
Tagawa Y, Laroy W, Nimrichter L, et al. Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids. Neurochem Res 2002; 27(7-8): 847–55
Arienti G, Carlini E, Laureti S, et al. Red blood cell ghosts are affected by adrenoleucodystrophy. Eur J Clin Invest 1996; 26(10): 917–22
Ho JK, Moser H, Kishimoto Y, et al. Interactions of a very long chain fatty acid with model membranes and serum albumin: implications for the pathogenesis of adrenoleukodystrophy. J Clin Invest 1995; 96(3): 1455–63
Bezman L, Moser HW. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet 1998; 76(5): 415–9
van Geel BM, Bezman L, Loes DJ, et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001; 49(2): 186–94
Dubey P, Raymond GV, Moser AB, et al. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr 2005; 146(4): 528–32
Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004; 104(3): 881–8
Shapiro E, Krivit W, Lockman L, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000; 356(9231): 713–8
Mahmood A, Dubey P, Raymond GV, et al. Evaluating survival in nontransplanted boys with cerebral phenotype of x-linked adrenoleukodystrophy. Annals Neurol 2005; 58: S2
Hudspeth MP, Raymond GV. Immunopathogenesis of adrenoleukodystrophy: current understanding. J Neuroimmunol 2007; 182(1–2): 5–12
Moser HW, Raymond GV, Lu SE, et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol 2005; 62(7): 1073–80
Costakos D, Abramson RK, Edwards JG, et al. Attitudes toward presymptomatic testing and prenatal diagnosis for adrenoleukodystrophy among affected families. Am J Med Genet 1991; 41(3): 295–300
Therrell BL, Adams J. Newborn screening in North American. J Inherit Metab Dis 2007 Aug; 30(4): 447–65
Rizzo C, Boenzi S, Wanders RJ, et al. Characteristic acylcarnitine profiles in inherited defects of peroxisome biogenesis: a novel tool for screening diagnosis using tandem mass spectrometry. Pediatr Res 2003; 53(6): 1013–8
Ishikawa Y, Minami R, Nakao T. Diagnosis of adrenoleukodystrophy using dried blood spots. Tohoku J Exp Med 1985; 146(1): 69–72
Hubbard WC, Moser AB, Tortorelli S, et al. Combined liquid chromatographytandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. Mol Genet Metab 2006; 89(1–2): 185–7
Acknowledgments
The authors wish to acknowledge the contribution of Dr Hugo W. Moser. Dr Moser conceived of this project and was instrumental in taking the initial steps of making it a reality. His death in January 2007 prevented him from seeing this project brought to completion.
The authors also wish to acknowledge the role of the United Leukodystrophy Foundation in providing funds for the initial steps. Additional grant support is presently pending and the authors note that they have a continued academic and scientific interest in newborn screening for adrenoleukodystrophy and other peroxisomal disorders.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raymond, G.V., Jones, R.O. & Moser, A.B. Newborn Screening for Adrenoleukodystrophy. Mol Diag Ther 11, 381–384 (2007). https://doi.org/10.1007/BF03256261
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256261